Akeso Inc.’s ivonescimab achieved “significantly better than expected” hazard ratio (HR) results across all PD-L1-positive populations in the China-based HARMONi-2 Phase III trial, which is comparing monotherapy with the anti-PD-1/VEGF bispecific antibody with Merck & Co., Inc.’s Keytruda (pembrolizumab) for the first-line treatment of non-small cell lung cancer (NSCLC) with positive PD-L1 expression (PD-L1 TPS >1%).
HR 'Significantly Better Than Expected' In Akeso's HARMONi-2 Trial in 1L NSCLC
Head-To-Head Study With Keytruda
Akeso's CEO has highlighted favorable hazard ratio results for the Chinese biotech's anti-PD-1/VEGF bispecific antibody ivonescimab in a head-to-head trial with Keytruda across Chinese NSCLC patients with positive PD-L1 expression in a first-line setting.
More from China
• By
Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
More from Focus On Asia
• By
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.